NCT05730452

Brief Summary

In Uganda, about 5% of children discharged after hospitalization for a serious infection will die in the weeks after returning home. Doctors and parents are often unaware of this period of vulnerability and are poorly equipped to identify or handle this critical situation. This project builds on past work to develop and evaluate models and technology to predict, before discharge, an individual child's risk of recurrent illness, as well as to provide additional post-discharge support to at-risk children. This study seeks to evaluate the effect of a novel "Smart Discharges" approach on childhood mortality and health seeking behaviour.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
11,700

participants targeted

Target at P75+ for not_applicable sepsis

Timeline
Completed

Started Jul 2017

Longer than P75 for not_applicable sepsis

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 16, 2017

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

December 9, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 15, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2024

Completed
Last Updated

February 15, 2023

Status Verified

February 1, 2023

Enrollment Period

6.5 years

First QC Date

December 9, 2022

Last Update Submit

February 14, 2023

Conditions

Keywords

sepsispediatricscritical carepatient discharges

Outcome Measures

Primary Outcomes (1)

  • Post-discharge mortality

    Rate of all-cause mortality within 6-months post-discharge

    From discharge until 6 months post-discharge

Secondary Outcomes (2)

  • Post-discharge re-admission

    From discharge until 6 months post-discharge

  • Post-discharge health seeking

    From discharge until 6 months post-discharge

Study Arms (2)

Phase 1: Observational, children 0-59 months of age

NO INTERVENTION

Phase 1: Observational only

Phase 2: Interventional, children 0-59 months of age

EXPERIMENTAL

Phase 2: Intervention

Behavioral: Risk-stratified discharge and post-discharge care

Interventions

Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms. Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)

Phase 2: Interventional, children 0-59 months of age

Eligibility Criteria

Age0 Days - 59 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children under five years of age
  • Admission with a proven or suspected infection
  • Provide written informed consent

You may not qualify if:

  • Refusal to participate
  • Previous enrolment in the study
  • Outside of hospital catchment
  • Language barrier
  • Direct admission following birth without having been discharged

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BC Children's Hospital Research Institute

Vancouver, British Columbia, V5Z 2X8, Canada

RECRUITING

Related Publications (6)

  • Nemetchek B, English L, Kissoon N, Ansermino JM, Moschovis PP, Kabakyenga J, Fowler-Kerry S, Kumbakumba E, Wiens MO. Paediatric postdischarge mortality in developing countries: a systematic review. BMJ Open. 2018 Dec 28;8(12):e023445. doi: 10.1136/bmjopen-2018-023445.

    PMID: 30593550BACKGROUND
  • Wiens MO, Kissoon N, Kumbakumba E, Singer J, Moschovis PP, Ansermino JM, Ndamira A, Kiwanuka J, Larson CP. Selecting candidate predictor variables for the modelling of post-discharge mortality from sepsis: a protocol development project. Afr Health Sci. 2016 Mar;16(1):162-9. doi: 10.4314/ahs.v16i1.22.

    PMID: 27358628BACKGROUND
  • Nemetchek BR, Liang LD, Kissoon N, Ansermino JM, Kabakyenga J, Lavoie PM, Fowler-Kerry S, Wiens MO. Predictor variables for post-discharge mortality modelling in infants: a protocol development project. Afr Health Sci. 2018 Dec;18(4):1214-1225. doi: 10.4314/ahs.v18i4.43.

    PMID: 30766588BACKGROUND
  • Wiens MO, Kumbakumba E, Larson CP, Ansermino JM, Singer J, Kissoon N, Wong H, Ndamira A, Kabakyenga J, Kiwanuka J, Zhou G. Postdischarge mortality in children with acute infectious diseases: derivation of postdischarge mortality prediction models. BMJ Open. 2015 Nov 25;5(11):e009449. doi: 10.1136/bmjopen-2015-009449.

    PMID: 26608641BACKGROUND
  • English LL, Dunsmuir D, Kumbakumba E, Ansermino JM, Larson CP, Lester R, Barigye C, Ndamira A, Kabakyenga J, Wiens MO. The PAediatric Risk Assessment (PARA) Mobile App to Reduce Postdischarge Child Mortality: Design, Usability, and Feasibility for Health Care Workers in Uganda. JMIR Mhealth Uhealth. 2016 Feb 15;4(1):e16. doi: 10.2196/mhealth.5167.

    PMID: 26879041BACKGROUND
  • Wiens MO, Kumbakumba E, Larson CP, Moschovis PP, Barigye C, Kabakyenga J, Ndamira A, English L, Kissoon N, Zhou G, Ansermino JM. Scheduled Follow-Up Referrals and Simple Prevention Kits Including Counseling to Improve Post-Discharge Outcomes Among Children in Uganda: A Proof-of-Concept Study. Glob Health Sci Pract. 2016 Sep 29;4(3):422-34. doi: 10.9745/GHSP-D-16-00069. Print 2016 Sep 28.

    PMID: 27628107BACKGROUND

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Matthew O Wiens, PharmD, PhD

    University of British Columbia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Matthew O Wiens, PharmD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Model Details: Before and after study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

December 9, 2022

First Posted

February 15, 2023

Study Start

July 16, 2017

Primary Completion

January 31, 2024

Study Completion

March 31, 2024

Last Updated

February 15, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will share

At each stage of the analysis and data preparation all of the study data will be prepared for public distribution. We will make every effort to prevent re-identification of subjects by coding data that has the potential of being identifiable. For example we will convert all dates into meaningful decimal numbers (date of birth into days since birth and date of recruitment will be reduced to month of recruitment) and all locations will coded into data that is useful but not specific (such as address converted to distance and direction from facility). We will ensure that data elements with small numbers of subjects (less than 10) will be coded or lumped to avoid identification. The study data will be made publically available using a reputable data hosting service (e.g. INDEPTH Data Repository, Dataverse etc.). During the data analysis stage, data lacking patient identifiers will be accessed from REDCap by team members involved in the statistical analysis.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data will be deposited to an open access repository with moderated access within 2 years of study completion
Access Criteria
Moderated access on a case-by-case basis.

Locations